In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

Journal of Antimicrobial Chemotherapy

Volumn 74, Issue 2, 2019, Pages 380-386

  Hsueh, Shun Chung ^a   Lee, Yuarn Jang ^a,b   Huang, Yu Tsung ^c,d   Liao, Chun Hsing ^c,e   Tsuji, Masakatsu ^f   Hsueh, Po Ren ^d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFEPIME; CEFIDEROCOL; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; IMIPENEM; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; BROTH DILUTION; COLISTIN RESISTANCE; IN VITRO STUDY; IRON DEPLETION; MIC50; MIC90; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; TAIWAN; DRUG COMBINATION; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTEREMIA; CEFTAZIDIME; CEPHALOSPORINS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; TAIWAN; TAZOBACTAM;

EID: 85060136030     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky425     Document Type: Article

References (20)

1. Molton JS, Tambyah PA, Ang BS et al. The global spread of healthcareassociated multidrug-resistant bacteria: A perspective from Asia. Clin Infect Dis 2013; 56: 1310-8.
2. Lai CC, Lee K, Xiao Y et al. High burden of antimicrobial drug resistance in Asia. J Glob Antimicrob Resist 2014; 2: 141-7.
3. Lee CM, Lai CC, Chiang HT et al. Presence ofmultidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. J Microbiol Immunol Infect 2017; 50: 133-44.
4. Hu YF, Hou CJ, Kuo CF et al. Emergence of carbapenem-resistant Acinetobacter baumannii ST787 in clinical isolates fromblood in a tertiary teaching hospital inNorthern Taiwan. JMicrobiol Immunol Infect 2017; 50: 640-5.
5. LinMF, Lin YY, Tu CC et al. Distribution of different efflux pump genes in clinical isolates of multidrug-resistant Acinetobacter baumannii and their correlation with antimicrobial resistance. J Microbiol Immunol Infect 2017; 50: 224-31.
6. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: Restoring the miracle or false dawn?. Clin Microbiol Infect 2017; 23: 704-12.
7. van Duin D, Bonomo RA. Ceftazidime/avibactamand ceftolozane/tazobactam: Second-generation b-lactam/b-lactamase inhibitor combinations. Clin Infect Dis 2016; 63: 234-41.
8. Carmeli Y, Armstrong J, Laud PJ et al. Ceftazidime/avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): A randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16: 661-73.
9. Ito-Horiyama T, Ishii Y, Ito A et al. Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases. Antimicrob Agents Chemother 2016; 60: 4384-6.
10. Hackel MA, Tsuji M, Yamano Y et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant Gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 2017; 61: Pii:e00093-17.
11. Hackel MA, Tsuji M, Yamano Y et al. In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 2018; 62: Pii:e01968-17.
12. Nordmann P, Vazquez-Rojo L, Poirel L. Stability of cefiderocol against clinically-significant broad-spectrum oxacillinases. In: Abstracts of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018. Abstract P0185. ESCMID, Basel, Switzerland.
13. Hsueh PR, Kuo LC, Chang TC et al. Evaluation of the Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of blood isolates of Acinetobacter species. J Clin Microbiol 2014; 52: 3095-100.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-eighth Informational Supplement M100-S28. CLSI, Wayne, PA, USA, 2018.
15. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoints (version 8.0, 2018). EUCAST, Basel, Switzerland, 2018. http://www.eucast.org/clinical-breakpoints/.
16. Huband MD, Ito A, Tsuji M et al. Cefiderocol MIC quality control ranges in iron-depleted cation-adjusted Mueller-Hinton broth using a CLSI M23-A4 multi-laboratory study design. Diagn Microbiol Infect Dis 2017; 88: 198-200.
17. Katsube T, Echols R, Arjona Ferreira JC et al. Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: Pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 2017; 57: 584-91.
18. TsujiM, HackelM, Echols R et al. The in-vitro activity of cefiderocol, a novel siderophore cephalosporin, against a global collection of Stenotrophomonas maltophilia. In: Abstracts of the Twenty-eighth European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018. Abstract P1313. ESCMID, Basel, Switzerland.
19. Tomaras AP, Crandon JL, McPherson CJ et al. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013; 57: 4197-207.
20. Ito A, Sato T, Ota M et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob Agents Chemother 2017; 62: Pii:e01454-17.